© 2017 Pharmstandard Ventures
TearSolutions
Charlottesville, VA, USA
Year of Investment: 2017
TearSolutions
Charlottesville, VA, USA
Year of Investment: 2017
TearSolutions is a clinical-stage biotechnology company spun out of the University of Virginia that is advancing a novel, first-in- class topical treatment for dry eye. The drug, LacripepTM, is a synthetic fragment of the human tear protein Lacritin discovered and developed with National Eye Institute funding. Topical LacripepTM is a breakthrough opportunity that in preclinical studies eliminates corneal staining and independently promotes basal tearing without irritation for hours by natural physiological processes.
For more information please visit:
www.tearsolutions.com
For more information please visit:
www.tearsolutions.com
Pharmstandard Ventures is looking for innovative drug discovery/development projects targeting the unmet medical needs or providing dramatic advantages over the competition globally